Primary Myelofibrosis News and Research

RSS
FDA approves new drug to treat patients with myelofibrosis

FDA approves new drug to treat patients with myelofibrosis

Detailed structure of protein pair offers blueprint for new medicines

Detailed structure of protein pair offers blueprint for new medicines

New genetic model identified for predicting outcomes in patients with primary myelofibrosis

New genetic model identified for predicting outcomes in patients with primary myelofibrosis

BUSM researchers show how MRI can effectively identify bone marrow cancer in experimental model

BUSM researchers show how MRI can effectively identify bone marrow cancer in experimental model

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Study provides new insight on cancer prevention

Study provides new insight on cancer prevention

Longer looks: People with mental disabilities have a vote; Genome sequencing raises hope - also anxiety

Longer looks: People with mental disabilities have a vote; Genome sequencing raises hope - also anxiety

Novartis receives EC approval for Jakavi to treat myelofibrosis

Novartis receives EC approval for Jakavi to treat myelofibrosis

CTI acquires world-wide rights to S*BIO’s pacritinib

CTI acquires world-wide rights to S*BIO’s pacritinib

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis